3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
4
Recruiting
2
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Recurrence
1
Neoplasms
1
Leukemia, Myeloid, Acute
1
Interventions
pembrolizumab
73
Carboplatin
60
Cyclophosphamide
59
Nivolumab
52
Paclitaxel
47
Gemcitabine
44
Cisplatin
43
Dexamethasone
41
Radiotherapy
36
Rituximab
32
Capecitabine
32
Bevacizumab
29
Docetaxel
28
fludarabine
27
atezolizumab
26
Cytarabine
26
avelumab
24
venetoclax
23
Trastuzumab
23
Oxaliplatin
23
Lenalidomide
23
Cetuximab
23
Azacitidine
23
Ipilimumab
22
Fluorouracil
22
Temozolomide
21
130-nm albumin-bound paclitaxel
21
fludarabine phosphate
20
Filgrastim
20
Bortezomib
20
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Terminated
×
enasidenib
×
Clear all
NCT04092179
2024-01-24
ENAVEN-AML
University Health Network, Toronto
Phase 1/2
Terminated
27 enrolled